Zimmer Biomet (NYSE:ZBH) Sets New 52-Week Low – Should You Sell?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $101.04 and last traded at $101.72, with a volume of 79557 shares trading hands. The stock had previously closed at $103.13.

Analysts Set New Price Targets

ZBH has been the topic of several research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Evercore ISI decreased their price objective on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research report on Thursday, December 12th. BTIG Research reduced their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Finally, Oppenheimer lowered their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $123.33.

Zimmer Biomet Stock Up 2.6 %

The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The stock has a market cap of $20.74 billion, a P/E ratio of 19.81, a P/E/G ratio of 1.96 and a beta of 1.02. The company’s 50 day moving average price is $108.09 and its two-hundred day moving average price is $108.05.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.65 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Hedge Funds Weigh In On Zimmer Biomet

A number of large investors have recently bought and sold shares of ZBH. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet during the third quarter valued at about $28,000. Bangor Savings Bank purchased a new position in Zimmer Biomet in the third quarter valued at about $31,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet in the third quarter valued at about $35,000. Finally, Quarry LP bought a new position in Zimmer Biomet in the second quarter worth about $53,000. Institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.